Sign Up to like & get
recommendations!
1
Published in 2022 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2022.2083324
Abstract: Abstract Objective Analysis and comparison of country-level data from the VISIONARY study, examining treatment outcomes with the topical fixed-dose combination of preservative-free tafluprost (0.0015%) and timolol (0.5%) (PF tafluprost/timolol FC) in adults with open-angle glaucoma…
read more here.
Keywords:
country level;
country;
study;
tafluprost timolol ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2135701
Abstract: ABSTRACT Introduction Elevated intraocular pressure (IOP) is the most important modifiable risk factor for irreversible sight loss in open-angle glaucoma (OAG). The topical fixed-dose combination (FC) of preservative-free (PF) tafluprost (0.0015%) and timolol (0.5%) (tafluprost/timolol)…
read more here.
Keywords:
glaucoma;
tolerability;
therapy;
tafluprost timolol ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Taiwan Journal of Ophthalmology"
DOI: 10.4103/tjo.tjo_108_17
Abstract: RELEVANCE: The ability of antiglaucoma drugs to improve ocular hemoperfusion is an important aspect of their action. Tafluprost is the first preservative-free prostaglandin analog. The efficacy and safety of tafluprost, as well as tafluprost/timolol fixed…
read more here.
Keywords:
newly diagnosed;
tafluprost timolol;
topical tafluprost;
group ... See more keywords